This results in increased levels of interferon-gamma (IFN-γ), TNFα, and interleukin-2 [246] and upregulating activating NK cell receptors such as natural killer group 2 member D (NKG2D), which is crucial for targeting NB cells, especially in conjugation with monoclonal antibody therapy like dinutuximab [247]. Here, IFNG is linked to neuroblastoma.